Categories
Archives
- 2026
- 2025
- 2024
- 2023
- 2022
- 2021
Oct
17
Steadfast Towards Our Ambition to Create a UCB Rare Disease Portfolio
Oct
12
Phase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis Suppurativa
Oct
04
UCB presents late-breaking posters at Child Neurology Society Meeting
Sep
11
UCB PharmD Second-Year Fellows Share Reflections and Advice
Sep
05
Announcing the 2023 UCB Family Epilepsy Scholarship Winners
Aug
03
Employee Spotlight: David Hornbaker’s Heart for Helping Patients
Aug
01
Evolving Expectations for Dermatological Conditions
Jul
21
UCB announces U.S. availability of RYSTIGGO® (rozanolixizumab-noli) for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive
Jun
27
Fulfilling Our Ambition to Deliver an FDA-Approved Treatment for People Living with Generalized Myasthenia Gravis
